Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

 

• Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg candidates

• Financing co-led by Fountain Healthcare Partners, Forbion and Andera Partners with support from existing investors

• Bernard Coulie appointed as Independent Chairman with immediate effect

 

Dualyx NV, a Ghent based biotech developing next generation immune modulators, today announces that it has completed a €40 million ($44 million) Series A financing.